Get the Stockscreener App
51.53
0.04%
0.02
Pre-market:
51.35
-0.18
-0.35%
Viking Therapeutics Inc stock is traded at $51.53, with a volume of 3.50M.
It is up +0.04% in the last 24 hours and down -21.69% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$51.51
Open:
$52.7
24h Volume:
3.50M
Relative Volume:
0.84
Market Cap:
$5.74B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-55.41
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
-6.41%
1M Performance:
-21.69%
6M Performance:
-23.68%
1Y Performance:
+337.81%
1-Day Range:
$50.40
$53.04
1-Week Range:
$47.65
$56.00
52-Week Range:
$11.21
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| VKTX | 51.53 | 5.74B | 0 | -99.15M | -74.25M | -0.93 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Viking Therapeutics is more than just a weight-loss stock, and that’s drawing cheers - MSN
NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors - Citeline News & Insights
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.5%Here's What Happened - MarketBeat
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Earns Outperform Rating from William Blair - MarketBeat
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 - The Malaysian Reserve
JW Asset Management LLC Makes New Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data - MSN
Is It Too Late to Buy Viking Therapeutics Stock? - MSN
Viking phase 2b study of NASH candidate hits primary endpoint - Seeking Alpha
Viking Therapeutics (NASDAQ:VKTX) Trading Down 1%Here's Why - MarketBeat
3 Things You Need to Know if You Buy Viking Therapeutics Today - AOL
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc.VKTX - PR Newswire
Viking Therapeutics (NASDAQ:VKTX) Shares Down 1.4%Here's What Happened - MarketBeat
What the Options Market Tells Us About Viking Therapeutics - Benzinga
Viking Therapeutics Insiders Sold US$8.9m Of Shares Suggesting Hesitancy - Simply Wall St
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia) - AOL
LJI Wealth Management LLC Has $1.17 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. - AOL
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On. - The Motley Fool
Viking Therapeutics (NASDAQ:VKTX) Shares Down 2.9%Should You Sell? - MarketBeat
Market Whales and Their Recent Bets on VKTX Options - Benzinga
Oppenheimer & Co. Inc. Has $6.48 Million Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Aptus Capital Advisors LLC Purchases 9,699 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Sigma Planning Corp Acquires Shares of 15,119 Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand? - Yahoo! Voices
Viking Therapeutics (NASDAQ:VKTX) Shares Down 3.1%Here's Why - MarketBeat
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? - sharewise
Chartwell Investment Partners LLC Acquires 17,159 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Is Viking Therepautics a Buy Now? - AOL
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 5.6%What's Next? - MarketBeat
Viking Therapeutics to Present Key NASH Drug Trial Results at Major Liver Meeting | VKTX Stock News - StockTitan
Viking Therapeutics (VKTX) Shares Cross Below 200 DMA - Nasdaq
Principal Financial Group Inc. Has $37.58 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Trading Down 2.2% After Insider Selling - MarketBeat
Is Viking Therapeutics a Buy on the Dip? - sharewise
291,318 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Purchased by Fiera Capital Corp - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) Director Sells 2,000 Shares of Stock - MarketBeat
Viking Therapeutics director sells $137,333 in stock - Investing.com
Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 0.8%What's Next? - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) is Quantum Private Wealth LLC's 10th Largest Position - MarketBeat
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move - sharewise
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat - MSN
Viking Therapeutics (NASDAQ:VKTX) Shares Up 0.3%Time to Buy? - MarketBeat
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag - MSN
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial - MSN
Viking Therapeutics (VKTX) Stock Surges on Promising Treatment Pipeline - Nasdaq
Viking Therapeutics Shines With Promising Results For New Obesity Drug - Finimize
Viking Therapeutics reports positive data from trial of treatment for rare metabolic disorder X-ALD - MSN
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):